AtaGenix Laboratories
AtaGenix Laboratories
AtaGenix offers diverse custom antibody discovery services to meet various research and industrial needs. Our expertise includes hybridoma sequencing, modified antibody development, rapid mouse monoclonal antibody generation, bispecific antibody development, small molecule antibody generation, phage display library screening, and the production of neutralizing/blocking and anti-idiotype antibodies.
A 2017 study developed a high-affinity anti-HE4 monoclonal antibody (9C3) using AtaGenix’s advanced mammalian expression and hybridoma platforms. This breakthrough enhances ovarian cancer diagnostics by targeting the HE4 biomarker with high specificity, offering potential for early detection and therapy.
This article highlights a 2021 Small Methods study that identified immunogenic peptides in the SARS-CoV-2 spike protein and isolated neutralizing monoclonal antibodies from COVID-19 patients. The research pinpointed key RBM epitopes (S431-454, S470-486, S501-515), with S470-486 emerging as an immunodominant target for diagnostics and therapeutics. Using phage display and ScFv libraries, the study validated epitope mapping and antibody functionality. Supported by AtaGenix’s expertise in phage display, protein expression, and assay development, this breakthrough offers a scalable approach for combating emerging viral pathogens, updated as of August 24, 2025.
Contact Us
+86-27-87001869
info@atagenix.com
Building C, R & D Building, No. 666, Shendun 4th Road, Donghu New Technology Development Zone, Wuhan
